Cargando…
Pyridoxine for prevention and treatment of PARP inhibitor induced nausea and vomiting
Poly-ADP ribose polymerase inhibitors (PARPi) are a promising new treatment option for patients with ovarian cancer and are moderately emetogenic. Tolerance of therapy is paramount, and uncontrolled nausea and vomiting may limit use. Although most patients will experience improvement in nausea and v...
Autores principales: | Ostby, Stuart A., Smith, Haller J., Leath, Charles A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722232/ https://www.ncbi.nlm.nih.gov/pubmed/31517011 http://dx.doi.org/10.1016/j.gore.2019.07.005 |
Ejemplares similares
-
The Delayed-Release Combination of Doxylamine and Pyridoxine (Diclegis(®)/Diclectin(®)) for the Treatment of Nausea and Vomiting of Pregnancy
por: Madjunkova, Svetlana, et al.
Publicado: (2014) -
Doxylamine succinate–pyridoxine hydrochloride (Diclegis) for the management of nausea and vomiting in pregnancy: an overview
por: Nuangchamnong, Nina, et al.
Publicado: (2014) -
Demonstration of early efficacy results of the delayed-release combination of doxylamine-pyridoxine for the treatment of nausea and vomiting of pregnancy
por: Koren, Gideon, et al.
Publicado: (2016) -
Doxylamine-pyridoxine for nausea and vomiting of pregnancy randomized placebo controlled trial: Prespecified analyses and reanalysis
por: Persaud, Navindra, et al.
Publicado: (2018) -
Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial
por: Koren, Gideon, et al.
Publicado: (2015)